Muriel de Seze/DigitalVision via Getty Images It's now been a year since IRIDEX (NASDAQ:IRIX) announced its strategic review to "unlock shareholder value." Thus far, the strategic review has been frustrating for shareholders (and, I imagine, the company!) as multiple events have taken place that has slowed down the ultimate sale of the company's assets, which clearly seems to be IRIX's end-game, in my view. The first major hurdle that came IRIX's way relates to a reimbursement issue I covered in a November ...